ClinicalTrials.gg
TerminatedNCT03379584Updated Sep 18, 2019

A Safety Study of SGN-CD48A in Patients With Multiple Myeloma

A Phase 1 interventional study of SGN-CD48A in Multiple Myeloma, sponsored by Seagen Inc.. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-18.

Sponsored by Seagen Inc. (part of Pfizer) · Phase 1, Interventional, and Treatment

Why this study was terminated
Due to overall benefit/risk profile

From the registry’s dates

  • Primary completion was Aug 2019, 7 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Multiple Myeloma by Pfizer — 6 open to participants now, 12 under way, 4 of them phase 3. Multiple Myeloma · Pfizer.

Enrollment
28th of 31
14 · median 77
Started
2018
with 2 others
Phase 1
16 of 44
none open now
Registered
16th of 44
by date

Among the 44 studies in Multiple Myeloma by Pfizer, this one is the 28th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2018, is one of 16 in phase 1, and was the 16th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

6 of the 44 studies in Multiple Myeloma by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 586 Multiple Myeloma studies recruiting now, 431 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Multiple Myeloma by Pfizer, or all of them as a file.
02

Study summary

This study will test the safety and activity of SGN-CD48A in patients with multiple myeloma. SGN-CD48A will be given on Days 1, 8, and 15 of a 28-day cycle. Prior to protocol amendment 2, SGN-CD48A was given every 3 weeks.

Read the detailed description

This study is designed to evaluate the safety, tolerability, and antitumor activity of SGN-CD48A in patients with relapsed or refractory multiple myeloma. This study will be conducted in 2 parts:

  1. Dose escalation: This part will evaluate increasing doses of SGN-CD48A to identify the maximum tolerated dose.

    The first group of patients enrolled on the study will receive the lowest dose of SGN-CD48A. Once this dose is shown to be safe, a second group of patients will be enrolled at the next higher dose. Patients will continue to be enrolled in groups receiving increasing doses until the maximum tolerated dose level is reached. Patients can only be enrolled into a higher dose level once the lower doses have been demonstrated safe. Dose escalation will be conducted using a modified toxicity probability interval (mTPI) study design.

  2. Dose expansion: This part will further evaluate the safety, tolerability, and antitumor activity of up to 2 dose levels of SGN-CD48A shown to be safe in the first part of the trial.
03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple myeloma
  • Antibody-drug conjugate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of MM requiring systemic therapy (per the International Myeloma Working Group [IMWG])
  • Patients must not have other therapeutic options known to provide clinical benefit in MM available to them. must include at least a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
  • Measureable disease, as defined by at least one of the following: serum M protein 0.5 g/dL or higher, urine M protein 200 mg/24 hour or higher, and serum immunoglobulin free light chain 10 mg/dL or higher and abnormal serum immunoglobulin kappa lambda free light chain ratio
  • Adequate hematologic, renal, and hepatic function
  • (ECOG) performance status of 0 or 1
  • greater than 3 months
  • A negative pregnancy test (for females of )
  • Patients must provide written consent

Exclusion criteria

Exclusion Criteria:

  • Pre-existing peripheral neuropathy Grade 2 or higher
  • History of other than MM within the past 3 years
  • Active cerebral/meningeal disease related to the underlying malignancy
  • Uncontrolled Grade 3 or higher infection
  • Known to be positive for or , or known to have active infection
  • Previous stem cell transplant
  • History of cerebral vascular event, unstable angina, myocardial infarction, or cardiac symptoms consistent with congestive heart failure within the last 6 months
  • Treatment with any known P-gp inducers/inhibitors or strong inhibitors within 14 days prior to the first dose of study drug
  • Prior antitumor therapy that is not completed at least 4 weeks prior to first dose of study drug, or at least 2 weeks if progressing. Prior CAR T-cell therapy must be completed 8 weeks before first dose of study drug.
  • Females who are pregnant or breastfeeding
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    SGN-CD48A

    SGN-CD48A

    Drug: SGN-CD48A

Interventions

  • DrugSGN-CD48A

    Intravenous (IV) infusion on days 1, 8, and 15 of a 28-day cycle

06

What researchers measure

Primary outcomes

  1. Type, incidence, severity, seriousness, and relatedness of adverse events

    Time frame: Through 1 month following last dose

  2. Incidence of laboratory abnormalities

    Time frame: Through 1 month following last dose

  3. Incidence of dose limiting toxicity

    Time frame: Through 3 weeks following first dose

Secondary outcomes

  1. Objective response rate

    The proportion of patients with stringent complete response, complete response, very good partial response, or partial response per investigator

    Time frame: Through 1 month following last dose

  2. Complete response rate

    The proportion of patients with stringent complete response or complete response per investigator

    Time frame: Through 1 month following last dose

  3. Duration of objective response

    Time frame: Up to approximately 3 years

  4. Duration of complete response

    Time frame: Up to approximately 3 years

  5. Progression-free survival

    Time frame: Up to approximately 3 years

  6. Overall survival

    Time frame: Up to approximately 3 years

  7. Blood concentrations of SGN-CD48A and metabolites

    Time frame: Through 1 month following last dose

  8. Incidence of antitherapeutic antibodies

    Time frame: Through 1 month following last dose

07

Study locations

6 sites
  • University of California at San Francisco
    San Francisco, California 94134, United States
  • Yale Cancer Center
    New Haven, Connecticut 06520, United States
  • H. Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
  • University of Pennsylvania / Perelman Center for Advanced Medicine
    Philadelphia, Pennsylvania 19104, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Aug 2019, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2017
First posted
Dec 20, 2017
StartActual
Feb 20, 2018
Primary completionActual
Aug 23, 2019
CompletionActual
Aug 23, 2019
Last update
Sep 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03379584
Lead sponsor
Seagen Inc.
Responsible party
Sponsor
First posted
Dec 20, 2017
Start date
Feb 20, 2018
Primary completion
Aug 23, 2019
Completion
Aug 23, 2019
Last update
Sep 18, 2019

Study contacts

Suzanne McGoldrick, MD, MPH
study director · Seagen Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion